Fig. 2.

Inclusion and exclusion criteria for round 1 interviews. AD Alzheimer’s disease, ADLs activities of daily living, meds medications, MCI mild cognitive impairment, Rx prescription. Note: The screening criteria were revised for round 2 interviews. The revisions included the following: time since a person first spoke with their doctor about memory concerns was decreased from 4 years to 2 years, participants who reported taking memantine (Namenda) or the combination of memantine and donepezil (Namzaric) were excluded, and those self-reporting that they were not comfortable with a computer were ineligible